JPWO2021090786A1 - - Google Patents

Info

Publication number
JPWO2021090786A1
JPWO2021090786A1 JP2021554928A JP2021554928A JPWO2021090786A1 JP WO2021090786 A1 JPWO2021090786 A1 JP WO2021090786A1 JP 2021554928 A JP2021554928 A JP 2021554928A JP 2021554928 A JP2021554928 A JP 2021554928A JP WO2021090786 A1 JPWO2021090786 A1 JP WO2021090786A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021554928A
Other versions
JP7356650B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021090786A1 publication Critical patent/JPWO2021090786A1/ja
Application granted granted Critical
Publication of JP7356650B2 publication Critical patent/JP7356650B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
JP2021554928A 2019-11-05 2020-11-02 ヒトｔ細胞白血病ウイルス１型（ｈｔｌｖ－１）関連疾患の診断方法 Active JP7356650B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019200986 2019-11-05
JP2019200986 2019-11-05
PCT/JP2020/041000 WO2021090786A1 (ja) 2019-11-05 2020-11-02 ヒトｔ細胞白血病ウイルス１型（ｈｔｌｖ－１）関連疾患の診断方法

Publications (2)

Publication Number Publication Date
JPWO2021090786A1 true JPWO2021090786A1 (ja) 2021-05-14
JP7356650B2 JP7356650B2 (ja) 2023-10-05

Family

ID=75848489

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021554928A Active JP7356650B2 (ja) 2019-11-05 2020-11-02 ヒトｔ細胞白血病ウイルス１型（ｈｔｌｖ－１）関連疾患の診断方法

Country Status (6)

Country Link
US (1) US20220404363A1 (ja)
EP (1) EP4056587A4 (ja)
JP (1) JP7356650B2 (ja)
BR (1) BR112022007705A2 (ja)
WO (1) WO2021090786A1 (ja)
ZA (1) ZA202204902B (ja)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004163121A (ja) * 2002-11-08 2004-06-10 Srl Inc 白血病の検出方法及びそのための試薬
JP2005147798A (ja) * 2003-11-13 2005-06-09 Miyazaki Tlo:Kk 成人ｔ細胞白血病診断薬
JP2008292474A (ja) * 2007-04-27 2008-12-04 Nationa Hospital Organization 成人ｔ細胞白血病発症リスク判定方法
JP2009254357A (ja) * 2008-03-19 2009-11-05 Okayama Univ 成人ｔ細胞白血病・リンパ腫の予後推定法およびキット
JP2013007742A (ja) * 2011-05-20 2013-01-10 Oita Univ 糖質プロファイリングによる血液腫瘍診断方法
JP2014059299A (ja) * 2012-08-24 2014-04-03 Nationa Hospital Organization 慢性型成人ヒトｔ細胞白血病（ａｔｌ）から急性型ａｔｌへの急性転化のし易さを試験する方法
JP2014059298A (ja) * 2012-08-24 2014-04-03 Nationa Hospital Organization 成人ｔ細胞白血病の発症し易さを試験する方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004163121A (ja) * 2002-11-08 2004-06-10 Srl Inc 白血病の検出方法及びそのための試薬
JP2005147798A (ja) * 2003-11-13 2005-06-09 Miyazaki Tlo:Kk 成人ｔ細胞白血病診断薬
JP2008292474A (ja) * 2007-04-27 2008-12-04 Nationa Hospital Organization 成人ｔ細胞白血病発症リスク判定方法
JP2009254357A (ja) * 2008-03-19 2009-11-05 Okayama Univ 成人ｔ細胞白血病・リンパ腫の予後推定法およびキット
JP2013007742A (ja) * 2011-05-20 2013-01-10 Oita Univ 糖質プロファイリングによる血液腫瘍診断方法
JP2014059299A (ja) * 2012-08-24 2014-04-03 Nationa Hospital Organization 慢性型成人ヒトｔ細胞白血病（ａｔｌ）から急性型ａｔｌへの急性転化のし易さを試験する方法
JP2014059298A (ja) * 2012-08-24 2014-04-03 Nationa Hospital Organization 成人ｔ細胞白血病の発症し易さを試験する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUERRERO C L H 、外１７名: "Proteomic profiling of HTLV-1 carriers and ATL patients reveals sTNFR2 as a novel diagnostic biomark", BLOOD ADV, vol. 4, no. 6, JPN6020050661, 2020, pages 1062 - 1071, XP055821542, ISSN: 0005059288, DOI: 10.1182/bloodadvances.2019001429 *

Also Published As

Publication number Publication date
EP4056587A1 (en) 2022-09-14
BR112022007705A2 (pt) 2022-07-12
US20220404363A1 (en) 2022-12-22
TW202124958A (zh) 2021-07-01
ZA202204902B (en) 2023-01-25
EP4056587A4 (en) 2023-11-22
WO2021090786A1 (ja) 2021-05-14
JP7356650B2 (ja) 2023-10-05

Similar Documents

Publication Publication Date Title
BR112019017762A2 (ja)
BR112021017339A2 (ja)
BR112021013854A2 (ja)
BR112021018450A2 (ja)
BR112021017939A2 (ja)
BR112021017892A2 (ja)
BR112019016141A2 (ja)
BR112021017738A2 (ja)
BR112021017782A2 (ja)
BR112019016142A2 (ja)
BR112019016138A2 (ja)
BR112021018168A2 (ja)
BR112021017728A2 (ja)
AU2020104490A5 (ja)
BR112021017234A2 (ja)
BR112021017355A2 (ja)
BR112021017173A2 (ja)
BR112021018102A2 (ja)
BR112021017083A2 (ja)
BR112021017637A2 (ja)
BR112021008711A2 (ja)
BR112021018452A2 (ja)
BR112021012348A2 (ja)
BR112021018250A2 (ja)
BR112021018084A2 (ja)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230815

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230907

R150 Certificate of patent or registration of utility model

Ref document number: 7356650

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150